SS-31

SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, designed to selectively target and stabilize cardiolipin in the inner mitochondrial membrane. Explored in over 150 peer-reviewed publications, SS-31 represents a novel class of mitochondria-targeting therapeutics that improve mitochondrial function through cardiolipin binding rather than traditional antioxidant mechanisms. The peptide's two positively charged amino acids enable preferential targeting to the negatively charged inner mitochondrial membrane, where it concentrates approximately 5000-fold. By stabilizing cardiolipin and preventing its peroxidation, SS-31 enhances electron transport chain supercomplex assembly, improves ATP production efficiency, reduces reactive oxygen species generation, and maintains mitochondrial membrane integrity. Clinical development has been extensive but mixed: while trials in heart failure and primary mitochondrial myopathy failed to meet primary endpoints, long-term studies showed functional improvements in cardiac and skeletal muscle. In September 2025, the FDA granted accelerated approval for SS-31 (FORZINITY™) to improve muscle strength in Barth syndrome patients, marking its first approved therapeutic indication. The compound has demonstrated promise in aging research, reversing age-related mitochondrial dysfunction and improving exercise tolerance. SS-31 continues investigation in multiple disease states including age-related macular degeneration, diabetic nephropathy, neurodegenerative conditions, and ischemia-reperfusion injury, with research suggesting broad therapeutic potential for conditions involving mitochondrial dysfunction.

Mitochondrial Function and Aging

• Reverses Age-Related Decline: Eight weeks of SS-31 treatment reversed age-related declines in maximum mitochondrial ATP production and oxidative phosphorylation coupling without increasing mitochondrial content, indicating improved mitochondrial quality over quantity ^[2]
• Exercise Tolerance: Treatment nearly doubled treadmill endurance in aged mice compared to untreated animals, with approximately 30% improvement over baseline performance and enhanced fatigue resistance ^[2]
• Redox Homeostasis: Restored cellular redox balance by reducing protein oxidative damage markers, increasing reduced glutathione levels, and reversing widespread cysteine S-glutathionylation modifications to patterns similar to younger animals ^[2]
• Functional Aging Improvements: Improved cardiac ejection fraction, global longitudinal strain, and blunted frailty score accumulation in aging mice without detectable changes in epigenetic or transcriptomic age markers ^[11]

Cardiolipin Stabilization and Electron Transport Chain

• Membrane Electrostatics: Reduces surface potential and dipole potential by partially neutralizing negative charge density through electrostatic interactions with lipid phosphates, enhancing protein binding and membrane organization ^[1]
• Supercomplex Assembly: Promotes assembly of electron transport chain supercomplexes (particularly SC2 and SC4) and stabilizes the ATP synthasome, improving oxidative phosphorylation efficiency independent of cardiolipin composition changes ^[1][9]
• Direct Protein Interactions: Interacts with proteins including Complex IV subunit NDUA4 and adenine nucleotide translocase (ANT1), modulating their function and assembly ^[1]

Cardiac Function and Heart Failure

• Human Heart Improvement: Improved function of electron transport chain components when associated with supercomplexes in human cardiac mitochondria from failing ventricles, with clinical improvements in left ventricular volumes ^[4]
• Canine Heart Failure Model: Significantly increased ejection fraction, normalized mitochondrial respiratory function, restored ATP/ADP ratio from 0.38 to 1.16, reduced ROS formation, and attenuated fibrosis comparable to ACE inhibitors and beta-blockers ^[10]
• Ischemia-Reperfusion Protection: Improved complex I and II substrate respiration by average of 56%, reduced hydrogen peroxide emissions by 33%, and partially restored cristae network connectivity (10% increase in networked cristae, 24% enhancement in intermitochondrial connectivity) ^[11]

Barth Syndrome and Genetic Mitochondrial Disease

• FDA Approved Indication: September 2025 FDA accelerated approval for FORZINITY™ to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg ^[5][6]
• Mitochondrial Morphology: Reduced autophagic vacuoles, restored normal mitochondrial morphology, decreased DRP1pS616 levels (counteracting pro-fission conditions), and restored compromised mitophagy pathway ^[5]
• Respiratory Capacity: Significantly improved state 3 and state 4 respiration rates, normalized state 3/post-oligomycin respiration ratio, and enhanced respiratory supercomplex organization without altering diagnostic MLCL/CL ratio ^[9]
• Clinical Trial Results: TAZPOWER trial's open-label extension (36-48 weeks) showed significant improvements in 6-minute Walk Test (+95.9 meters, p=0.024), Barth syndrome Symptom Assessment, and heart physiology despite initial blinded phase not meeting primary endpoints ^[9]

Neuroprotection and Neuroinflammation

• Cognitive Function: Significantly ameliorated LPS-induced learning and memory impairment across Morris water maze and fear conditioning tasks while maintaining mitochondrial membrane potential and restoring hippocampal ATP production ^[3]
• Anti-inflammatory Effects: Substantially reduced IL-6 and TNF-α, suppressed inflammatory markers including COX-2, iNOS, NLRP3, cleaved caspase-1, IL-1β, and IL-18 ^[3][8]
• Oxidative Stress Reduction: Decreased hydrogen peroxide, lipid peroxidation, ROS levels, and malondialdehyde while restoring superoxide dismutase activity ^[3][8]
• Synaptic Preservation: Enhanced BDNF pathway signaling, prevented decline of synaptic structural proteins, maintained dendritic spine density and synaptic complexity, and prevented neural apoptosis ^[3][8]
• Mitochondrial Quality: Enhanced mitochondrial respiration, activated neural mitochondrial biogenesis, promoted fusion while inhibiting fission, and reduced amyloid-beta accumulation in Alzheimer's models ^[8]

Kidney Protection

• Diabetic Nephropathy: Alleviated proteinuria, reduced urinary 8-hydroxy-2-deoxyguanosine and H2O2 levels, decreased glomerular hypertrophy, reduced accumulation of renal fibronectin and collagen IV, attenuated renal cell apoptosis, and fully preserved renal superoxide production levels ^[14][15]
• Renal Artery Stenosis: Phase 2a trial showed elamipretide reduced fractional hypoxia (-6% vs +47% in placebo at 24 hours), increased stenotic kidney renal blood flow (202±29 to 262±115 ml/min, p=0.04), and significantly improved eGFR during stent revascularization ^[12]
• Ischemia-Reperfusion: Protected mitochondrial structure and respiration, reduced fibroblast and macrophage infiltration, improved apoptosis and renal tubular cell regeneration in obstructive injury models ^[14]

Retinal Protection and Vision

• Intermediate AMD and High-Risk Drusen: Phase 1 ReCLAIM trial showed best-corrected visual acuity improved by +3.6 letters (p=0.014), low-luminance visual acuity gained +5.6 letters (p=0.004), and reading acuity improved by approximately 1 line under normal luminance and 3 lines under low luminance ^[16]
• Dry AMD and Geographic Atrophy: ReCLAIM NCGA study demonstrated low-luminance visual acuity improved by +5.4 letters (p=0.0245), standard visual acuity improved by +4.6 letters (p=0.0032), and low-luminance reading acuity showed approximately 5-line improvement (p=0.005) ^[17]
• Functional Vision: Significant improvements in 6 of 7 low-luminance questionnaire subscales, suggesting benefits for daily activities like dim-light reading and dusk driving ^[16][17]
• Safety Profile: Generally safe and well tolerated in retinal applications with minimal geographic atrophy progression comparable to natural history studies ^[16][17]

Clinical Safety Profile

• Generally Well Tolerated: Comprehensive review of over 150 peer-reviewed publications and multiple clinical trials demonstrates favorable safety profile with no serious systemic adverse events in most studies ^[1][4][10]
• Most Common Side Effects: Injection site reactions are the primary concern, typically mild (57-73.7%) or moderate (26.3-43%), including redness, itching, or irritation that resolve spontaneously ^[14][16][17]
• Low Discontinuation Rate: Only 1 patient discontinued in the ReCLAIM AMD trials due to injection site intolerance; similarly low discontinuation rates observed across other clinical programs ^[16][17]
• Long-term Chronic Therapy: Multi-year treatment trials in dogs with heart failure and extended open-label extensions in Barth syndrome patients showed sustained safety without severe adverse events ^[6][10]

Regulatory Status

• FDA Approved: September 2025 FDA accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg - first approved therapeutic indication ^[5][6]
• Investigational Status: Remains investigational for all other indications including heart failure, primary mitochondrial myopathy, age-related macular degeneration, diabetic nephropathy, and neurodegenerative conditions ^[1]
• Clinical Trial History: Multiple completed trials including TAZPOWER (Barth syndrome), MMPOWER-3 (primary mitochondrial myopathy), PROGRESS-HF (heart failure), ReCLAIM (AMD), and renal artery stenosis studies ^{[1][5][12][16][17]}

Clinical Trial Outcomes

• Mixed Results: While showing promise in preclinical studies, clinical trials in heart failure (PROGRESS-HF) and primary mitochondrial myopathy (MMPOWER-3) failed to meet primary endpoints in initial blinded phases ^[1][6]
• Long-term Benefits: Open-label extensions and extended treatment periods (36-48 weeks) demonstrated significant improvements in functional outcomes including 6-minute walk test, cardiac function, and symptom assessments ^[5][6][11]
• Subgroup Efficacy: MMPOWER-3 subgroup analyses revealed significant benefit in patients with specific nuclear DNA mutations, leading to more targeted follow-up studies ^[6]

Dosing and Administration

• Barth Syndrome Approved Dose: 40 mg/day subcutaneous administration (based on TAZPOWER trial protocol) ^[5][6]
• Clinical Trial Dosing Range: Studies used 0.25 mg/kg/hour IV infusion (MMPOWER), 40 mg/day subcutaneous (ReCLAIM, TAZPOWER), and various dosing regimens depending on indication ^{[6][12][16][17]}
• Animal Studies: Preclinical research used doses ranging from 1-3 mg/kg in mice, with approximately 5000-fold concentration in mitochondria ^[2][14]

Specific Population Safety

• Pediatric Use: FDA approval includes pediatric patients with Barth syndrome weighing at least 30 kg, with safety data from clinical trials ^[5]
• Elderly Patients: ReCLAIM trials in patients ≥55 years showed excellent tolerability with functional improvements and no age-related safety concerns ^[16][17]
• Renal Disease: Phase 2a trial in atherosclerotic renal artery stenosis reported no adverse effects such as fever, rash, headache, or nausea during mitochondrial protection therapy ^[12][14]

Known Limitations and Contraindications

• Injection Site Tolerance: Subcutaneous administration requires patient tolerance for daily injections; mild injection site reactions are expected ^[16][17]
• Disease-Specific Efficacy: While safe, efficacy varies significantly by disease state and patient population; genetically diverse populations showed less benefit than specific genetic mutations ^[6]
• Trial Design Challenges: Ultra-rare diseases like Barth syndrome present challenges in trial design, with initial blinded phases failing despite long-term open-label benefits ^[5]

Mechanistic Safety Considerations

• Cardiolipin Interaction: Works through stabilizing cardiolipin rather than direct antioxidant effects, which may explain favorable safety profile compared to traditional mitochondrial therapies ^[1][9]
• No Lipid Remodeling: Benefits occur without changing cardiolipin composition or MLCL/CL ratio, suggesting acute stabilization mechanisms without long-term lipid metabolism interference ^[4][9]
• Selective Targeting: Approximately 5000-fold concentration in mitochondria minimizes off-target effects while maximizing therapeutic concentration at site of action ^[14]

Research Gaps

• Long-term Human Data: While animal studies show safety over entire lifespan and human trials show multi-year safety, comprehensive long-term toxicology data in broader human populations remains limited ^[2][10]
• Optimal Dosing: Dose-response relationships and optimal dosing strategies for different indications require further investigation ^[1]
• Combination Therapies: Safety and efficacy in combination with other mitochondrial-targeting or disease-modifying therapies not extensively studied ^[1]